

1 **The intravenous support type and volume is associated with the outcome and the major**  
2 **complications in patients with chronic intestinal failure**

3

4 Loris Pironi, Ezra Steiger, Francisca Joly, Geert Wanten, Cecile Chambrier, Umberto Aimasso, Anna Simona  
5 Sasdelli, Kinga Szczepanek, Amelia Jukes, Simona Di Caro, Miriam Theilla, Marek Kunecki, Joanne Daniels,  
6 Mireille Serlie, Florian Poullenot, Sheldon C. Cooper, Henrik H. Rasmussen, Charlene Compher, Adriana  
7 Crivelli, Maria C. Pagano, Sarah-Jane Hughes, Francesco W. Guglielmi, Nada Rotovnik Kozjek, Stéphane M.  
8 Schneider, Lars Ellegard, Ronan Thibault, Przemysław Matras, Anna Zmarzly, Konrad Matysiak, André Van  
9 Gossum, Alastair Forbes, Nicola Wyr, Marina Taus, Nuria M. Virgili, Margie O'Callaghan, Brooke Chapman,  
10 Emma Osland, Cristina Cuerda, Peter Sahin, Lynn Jones, Andre Dong Won Lee, Luisa Masconale, Paolo  
11 Orlandoni, Corrado Spaggiari, Maryana Doitchinova-Simeonova, Carmen Garde, Aurora E. Serralde-Zúñiga,  
12 Gabriel Oliveira, Zeljko Krznaric, Estrella Petrina Jáuregui, Ana Zugasti Murillo, José P. Suárez-Llanos and  
13 Simon Lal.

14 The Home Artificial Nutrition and Chronic Intestinal Failure special interest group of ESPEN, the European  
15 Society for Clinical Nutrition and Metabolism

16

17 Corresponding author

18 Loris Pironi

19 Center for Chronic Intestinal Failure

20 Department of Digestive System

21 St. Orsola Hospital, University of Bologna

22 Via Massarenti, 9 - 40138 Bologna, Italy

23 Tel: +39 - 051 - 6363073

24 Fax: +39 - 051 -6364193

25 Email: [loris.pironi@unibo.it](mailto:loris.pironi@unibo.it)

26 **What is already known on this subject?**

27           Previous studies have demonstrated that several clinical risk factors are associated with outcome and  
28 the risk of parenteral nutrition/intestinal failure-related major complications in patients on long-term home  
29 parenteral nutrition. However, no objective indicator has yet been identified to categorize the severity of  
30 chronic intestinal failure.

31 **What are the new findings?**

32           The one-year odds of death, major complications of parenteral nutrition/intestinal failure (liver  
33 disease and catheter-related blood stream infection), and of weaning from home parenteral nutrition are  
34 independently associated with the type and volume of the intravenous supplementation required.

35 **How might it impact on clinical practice in the foreseeable future?**

36           The type and the volume of the intravenous supplementation could be indicators to categorize the  
37 severity of chronic intestinal failure in clinical and research settings.

38 **Abstract**

39 **Background and aim**

40 No marker to categorize the severity of chronic intestinal failure (CIF) has yet been developed. A  
41 one-year international survey was carried out to investigate whether the European Society for Clinical  
42 Nutrition and Metabolism (ESPEN) clinical classification of CIF, based on the type and the volume of the  
43 intravenous supplementation (IVS), could be an indicator of CIF severity.

44 **Methods**

45 At baseline, participating home parenteral nutrition (HPN)-centers enrolled all adults with CIF due to  
46 non-malignant disease; demographic data, body mass index, CIF mechanism, underlying disease, HPN  
47 duration and IVS category were recorded for each patient. The type of IVS was classified as fluid and  
48 electrolyte alone (FE) or parenteral nutrition admixture (PN). The mean daily PN volume, calculated on a  
49 weekly basis, was categorized as: <1, 1-2, 2-3, >3 L/day. The severity of CIF was determined by patient  
50 outcome (still on HPN, weaned from HPN, deceased) and the occurrence of major HPN/CIF-related  
51 complications: intestinal failure associated liver disease (IFALD), catheter-related venous thrombosis (CVC-  
52 VT) and catheter-related bloodstream infection (CRBSI).

53 **Results**

54 Fifty-one HPN-centers included 2194 patients. Multiple regression analysis showed that both IVS type  
55 and volume were independently associated with the odds of weaning from IVS (higher for PN <1 L/day than  
56 for FE and all PN of >1 L/day), patient's death (higher for PN 2-3 and >3 L/day than for FE), presence of  
57 IFALD-cholestasis/liver failure and occurrence of CRBSI (progressively higher for PN 2-3 and PN >3 L/day  
58 than for FE).

59 **Conclusions**

60 The type and the volume of the IVS required by patients with CIF could be indicators to categorize  
61 the severity of CIF in both clinical practice and research protocols.

62 **Introduction**

63 Intestinal failure (IF) is defined as the reduction of gut function below the minimum necessary for the  
64 absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation (IVS) is  
65 required to maintain health and/or growth [1]. Chronic intestinal failure (CIF) is a long-lasting condition that  
66 may be reversible or irreversible. Patients with CIF are metabolically stable and receive IVS at home (home  
67 parenteral nutrition, HPN) for months, years or lifelong [2]. Single or multicenter, mostly retrospective,  
68 surveys have described risk factors associated with the patient's outcome, such as survival and reversibility  
69 of CIF, and with the risk of HPN/IF-related major complications [3-5]. However, no simple indicator, such as  
70 creatinine for kidney disease and SaO<sub>2</sub> for respiratory disease, has yet been identified to categorize the  
71 severity of CIF. Such an indicator would be a useful criterion for both clinical practice and research  
72 protocols.

73 The European Society for Clinical Nutrition and Metabolism (ESPEN) devised a clinical classification of  
74 CIF, to facilitate communication among professionals through an objective categorization of the patients.  
75 This was based on patients' requirements for energy and volume of IVS and originally comprised 16  
76 categories [1]. An international cross-sectional survey was carried out to investigate the applicability of this  
77 classification and to evaluate factors associated with the IVS requirements of individual patients [6]. In  
78 adult patients with CIF due to non-malignant disease (benign-CIF), the loss of intestinal function appeared  
79 more comprehensively represented by IVS volume requirement than by energy requirement. The results  
80 enabled the derivation of a new simplified 8-category classification of CIF, based on two types of IVS, either  
81 fluid and electrolyte alone (FE) or parenteral nutrition admixture containing energy (PN), and four  
82 categories of volume [6].

83 In order to determine whether ESPEN clinical classification categories could be used as indicators of  
84 the severity of CIF, a prospective, multi-center international study was carried out to investigate their  
85 association with the patient's outcome and the major complications related to HPN/IF. The results of one-  
86 year of follow up are reported.

87

88 **Material and methods**

89 *Study design*

90 This was an international survey involving the retrospective analysis of data prospectively recorded  
91 during a one-year follow-up period. The severity of CIF was based on both patient outcome and major  
92 complications related to HPN/IF. The patient's outcome was categorized as still on IVS, weaned from IVS or  
93 deceased. The HPN/IF-related complications were described as the occurrence of intestinal failure  
94 associated liver disease cholestasis (IFALD-cholestasis) and of central venous catheter associated vein  
95 thrombosis (CVC-VT) or central venous catheter related bloodstream infection (CRBSI) at one-year follow-  
96 up [2].

97 *Baseline HPN center enrollment and patient inclusion*

98 The baseline data collection was performed on March 1<sup>st</sup>, 2015. Details regarding HPN center  
99 enrollment and the patient inclusion criteria have been published in the previous cross-sectional survey  
100 carried out to evaluate the applicability the clinical classification of CIF [4]. Sixty-five HPN centers from 22  
101 countries enrolled all adult patients ( $\geq 18$  years old) dependent on IVS for CIF on March 1<sup>st</sup>, 2015. Patients  
102 with either benign or malignant disease were included. Patients with active malignant disease were termed  
103 as having "cancer-CIF". Patients without malignant disease at time of inclusion in the study were termed as  
104 having "benign-CIF". Invasive intra-abdominal desmoid disease was included in the benign group, because  
105 of the chronic nature of the condition and reflecting the fact that it is an established indication for intestinal  
106 transplantation [2]. A total of 3239 patients, 9.9% with cancer-CIF and 91.1% with benign-CIF were included  
107 [4]. For the purpose of the present study, only patients with benign-CIF were investigated.

108 *Follow up data collection*

109 The one-year follow up was carried out on patients enrolled in the 2015 baseline cross-sectional  
110 study. In February 2016, the study coordinator (LP) sent an email to the HPN centers that participated in  
111 the 2015 cross-sectional survey, to invite them to participate in the follow up. The study protocol and the  
112 structured database for the data collection were attached to the invitation letter. Centers were asked to  
113 include relevant data from the patient's medical records between March 1<sup>st</sup> 2015 and March 1<sup>st</sup> 2016 and  
114 details of the patient's outcome on March 1<sup>st</sup> 2016.

115 Data were collected into a structured questionnaire embedded in an Excel (Microsoft Co., 2013)  
116 database (the ESPEN CIF Action Day database). The items of the questionnaire are shown in **Table 1**.

#### 117 *Ethical statement*

118 The study was approved by the Home Artificial Nutrition and Chronic Intestinal Failure (HAN&CIF)  
119 special interest group of ESPEN. The research was based on anonymized information taken from patient  
120 records at time of data collection. The study was conducted with full regard to confidentiality of the  
121 individual patient. Ethical committee approval was obtained by the individual HPN centers according to  
122 local regulations. The collected data were used only for the study purpose. Contributing centers have been  
123 anonymized for data analysis and presentation.

#### 124 *Statistical analysis*

125 Data are reported as mean  $\pm$  standard deviation (SD), median and range, absolute and relative  
126 frequencies. For bivariate analysis involving categorical variables non-parametric tests such as Pearson's chi  
127 squared or Fisher's exact test were used, while in case of a categorical and a continuous variable the  
128 parametric one-way ANOVA (analysis of variance) or the non-parametric Kruskal-Wallis test were  
129 performed.

130 Logistic regression was carried out for multivariate analysis. The odds ratio was used to measure the  
131 association between the variables and the patient outcome or the presence of HPN/IF-complications. Two-  
132 tailed p values less than 0.05 were considered as statistically significant.

133 The analyses were performed using the IBM SPSS Statistics package for Windows, version 23.0 (BM  
134 Co., Armonk, NY, USA) and the R software for Windows, version 3.5.1 (<http://cran.r-project.org>).

135 **Results**

136 *Study population*

137 Fifty-one of the 65 HPN-Centers which contributed in the 2015 database collection, participated in  
138 the 2016 follow up; this included 2194 of the 2919 benign-CIF (75.1%) patients enrolled in 2015. Most of  
139 the patients (79.7%) were from European Countries, the remaining were from Israel, US, Mexico, Argentina,  
140 Brazil and Australia. The mean number of patients included in the follow up by center was  $43.0 \pm 54.1$   
141 (median: 19; range: 1-231).

142 **Table 2** shows the baseline characteristics of the cohort of patients with benign-CIF included in the  
143 present study. Two-thirds were female. The median (range) patient age, BMI and IVS duration were 56.5  
144 years (18.0-98.0), 21.7 kg/m<sup>2</sup> (10.5-59.6) and 33.2 months (0-474), respectively. SBS-J was the most  
145 frequent pathophysiological mechanism of IF (35.9% of cases). The most frequent underlying disease was  
146 Crohn's disease (21.1%).

147 The type of IVS was FE in 7.9% of patients and PN in 92.1%. The IVS volume was significantly lower in  
148 the subgroup of patients receiving FE (median 857.1 mL/day, range 107.1–4800.0) than in those receiving  
149 PN (median 1785.7 mL/day, range 81.7-7542.8) ( $P < 0.001$ ).

150 *One-year outcome*

151 At March 1<sup>st</sup>, 2016, 1740 (79.3%) patients were still on IVS, 298 (13.6%) were weaned from IVS and  
152 156 (7.1%) were deceased. The reason for weaning from IVS was reported in 272 cases: spontaneous  
153 intestinal adaptation in 138 (50.7%), non-transplant surgery in 114 (41.9%); surgical intestinal continuity  
154 reconstruction in 97 cases), ITx in 14 (5.1%) and intestinal growth factor therapy in 6 (2.2%) cases. The  
155 cause of death was reported in 146 cases: HPN/IF-related in 6 (4.1%) patients (CRBSI 5, IFALD 1), underlying  
156 disease-related in 64 (43.8%) (4 due to ITx complications) and other causes (neither HPN/IF nor underlying  
157 disease-related) in 76 (52.1%) cases. The bi-variate analysis (**Table 3**) showed that the patient's outcome  
158 was associated with the patient's age and BMI, the duration of IVS, the mechanism of IF, the underlying  
159 disease and the IVS categories (either FE or PN).

160 *Presence or occurrence of HPN/IF-complications at the end of the one-year follow up*

161 This item was recorded in 1859 of the 2194 (84.7%) patients. The presence of IFALD-cholestasis/liver  
162 failure was reported in 97 patients (4.4%): cholestasis 63 (64.9%), impending liver failure 11 (11.3%), overt  
163 liver failure 18 (18.6%), not specified 5 (5.1%). A CVC-VT was present in 53 patients (2.9%), 30 of which  
164 occurred during the one-year follow up. During the follow up, 273 patients (14.7%) had 344 episodes of  
165 CRBSI: one episode in 224 (82.0%); two episodes in 40 (14.7%); three episodes in 5 (1.8%); four episodes in  
166 2 (0.7%); 7 and 10 episodes in 1 (0.4%) patient each one. The bi-variate analysis (**Table 4**) showed that: the  
167 presence of IFALD-cholestasis/liver failure was associated with the patient's gender and with both the CIF  
168 clinical classification categories of IVS and the type of IVS. The presence of CVC-VT was associated with the  
169 duration of IVS, the mechanism of IF and the CIF clinical classification categories of IVS. The occurrence of  
170 CRBSI was associated with the patient's age and BMI, the underlying disease and with both the CIF clinical  
171 classification categories of IVS and the type of IVS.

172

173 *Multivariate analysis of factors associated with the patient's one-year outcome and HPN/IF-*  
174 *complications*

175 Weaning from IVS, death, presence of IFALD-cholestasis/liver failure or CVC-VT at the end of the  
176 follow up, and occurrence of CRBSI during the one-year of follow up were considered the dependent  
177 variables. The baseline demographics, IF mechanism, underlying disease and IVS characteristics were  
178 included as independent variables.

179 The association with either the IVS type or the IVS volume was investigated through two models of  
180 analysis:

- 181 a) *the IVS type model*, to analyze the association with either FE or PN; because of the statistically  
182 significant differences between the total FE and the total PN groups observed in the bivariate  
183 analyses, as well as of the low number of patients receiving the FE type, in this analysis the total FE  
184 group was considered the comparator group to be compared with the four PN groups;
- 185 b) *the PN volume model*, to analyze the association with the volume of the PN type of IVS; in this model,  
186 only patients receiving PN were included in the analysis and the lowest PN volume (PN1) was  
187 considered as the comparator group



188

189 *One-year outcome odds (Tables 5 and 6)*

190 In the whole group of patients, the odds of weaning from IVS (**Table 5**): a) were higher in the smallest  
191 PN1 type category (mean volume:  $695.3 \pm 216.8$  mL/day) than in the FE type category (mean volume:  
192  $1055.8 \pm 859.6$  mL/day,  $P < 0.001$ ), while no difference was observed between FE and the other PN volume  
193 categories; b) were lower in the greatest PN volume categories (PN2, PN3 and PN4), in comparison with  
194 PN1, the smallest PN volume; c) were similar between the two models for all the other independent  
195 factors: they were lower in the oldest decades of age, in the longest duration of IVS categories, in the  
196 miscellaneous group of underlying diseases and were higher in the underweight, overweight and obese  
197 BMI categories. . The multivariate analysis for the odds of weaning from IVS was repeated after excluding  
198 those patients who were weaned because of a non-transplant surgical procedure (**Table 6**). The results  
199 confirmed the higher odds associated with the PN1 IVS, the patient's age and duration of IVS, but not with  
200 the patient's BMI. Significant lower odds of weaning were observed in patients who had SBS-J or SBS-JC as  
201 mechanisms of IF and in those who had an underlying disease categorized in the miscellaneous group.

202 The odds of death on IVS: a) were higher in all the PN volume categories in comparison with the FE  
203 type category, even though this was statistically significant only with the greatest PN volumes, but no  
204 association was observed when only the PN volume categories were compared; b) were similar between  
205 the two models for all the other independent factors: they were higher in the oldest age categories, in the  
206 lowest BMI categories; in comparison with SBS-J mechanism of IF, the odds of death were lower in the SBS-  
207 JC group and were higher in with the other mechanisms of IF, excepting the extensive mucosal disease; the  
208 likelihood of death was increased in the mesenteric ischemia and decreased in the CIPO groups of  
209 underlying disease.

210

211 *Odds of major complications of HPN/IF (Table 7)*

212 The odds of the presence of IFALD-cholestasis/impending or overt liver failure: a) were progressively  
213 higher in the greatest PN volume categories (PN3 and PN4), in comparison to both the FE type of IVS and  
214 the PN1 and PN2 volumes; b) were similar between the two models of analysis for all the other

215 independent factors: in comparison with SBS-J, the likelihood of IFALD was lower in dysmotility mechanism  
216 of IF and higher in the group with surgical complications as their underlying disease.

217 The odds of the presence of CVC-VT: a) showed no association with the IVS categories; b) were  
218 similar between the two models of analysis for all the other independent factors: they were higher in the in  
219 the longest IVS duration categories and in the underweight category of BMI.

220 The odds of the occurrence of an episode of CRBSI: a) were progressively higher with the increase of  
221 the volume of the PN in comparison to both the FE type of IVS and the PN1 and PN2 volumes ; b) were  
222 similar between the two models of analysis for all the other independent factors: they were lower in older  
223 patients and were higher in the obese category of BMI and in the CIPO underlying disease

224 **Discussion**

225 This is the first study aimed at investigating the association between IVS requirement, CIF outcome  
226 and the occurrence of major complications in a very large international cohort of IVS-dependent patients  
227 with CIF due to benign underlying disease. The results show that both the type and the volume of the IVS  
228 are independently associated with the odds of weaning from IVS at one-year, as well as with the risk of  
229 mortality, the occurrence of CRBSI and the presence of IFALD-cholestasis/liver failure. In patients with CIF,  
230 the type and the volume of the IVS requirement primarily depends on the degree of the reduction of gut  
231 function (6). However, other factors may be involved, such as the patient's metabolic condition and vital  
232 organ function, the patient's compliance with the prescribed treatment as well as the treatment protocols  
233 of the multidisciplinary team caring for him/her (1,2). Therefore, while any association between IVS  
234 characteristics and the patient's outcome or the occurrence of HPN/IF complications may not be  
235 considered causal, they may indicate that the type and the volume of the IVS reflect comprehensive odds of  
236 morbidity and mortality for IVS-dependent patients, independently from the factors that may have  
237 determined their prescription. This is further strengthened by the observation that none of the other  
238 independent factors entered in the multiple regression analyses was contemporaneously associated with  
239 odds of weaning from IVS, death, or occurrence of IFALD and CRBSI. These data support the potential role  
240 of the ESPEN clinical classification of CIF, based on the type and the volume of the IVS, as a potential  
241 indicator of CIF severity. Further follow up surveys are required to investigate if this could be translated  
242 into a long-term marker of CIF.

243 The one-year odds of death depended on the interaction between the IVS type and volume rather  
244 than on either characteristic alone. Indeed, an increased likelihood of death was observed in those  
245 receiving the greatest volumes of PN rather than those receiving the FE, but no association was found with  
246 PN-volume alone; since HPN-related deaths were very rare (3), these results would suggest a less severe  
247 clinical condition in patients with CIF requiring only FE supplementation.

248 The one-year likelihood of weaning from IVS was associated with both the type and volume of IVS.  
249 The PN1 volume ( $\leq 1$  L/day) showed higher odds of weaning than either the greater PN-volumes or FE-type  
250 IVS. There could be several reasons for a longer maintenance of low volume FE than of low volume PN IVS:

251 a more difficult intestinal rehabilitation of fluid and electrolytes than of macronutrient absorption due to  
252 concomitant secondary mechanisms of IF causing increased intestinal secretion (1); the concomitant  
253 presence of reduced kidney function requiring the maintenance of optimal hydration (2,7); physician's  
254 and/or patient's perception of a lower risk of IVS-associated complications with FE than with PN; patient's  
255 better acceptance of FE than of PN, because of shorter duration of FE infusion compared to PN (2); the  
256 lower cost of FE. All of these factors would make weaning from FE slower/less likely than weaning from PN.

257 The likelihoods of IFALD and of the occurrence of CRBSIs were also associated with both the type and  
258 the volume of the IVS, whereas no association was observed with the presence of CVC-VT (**Tables 4 and 7**).  
259 The odds of IFALD and of CRBSI were greater in patients receiving the highest volumes of PN in comparison  
260 with the lowest PN-volumes and the FE-type of IVS. Furthermore, there was a progressive increase in  
261 likelihood of these complications with increased PN volume. These data are in keeping with previous  
262 studies (2,8,9). The pathogenesis of IFALD is multifactorial, including factors related to the IVS, underlying  
263 gastrointestinal disease and systemic factors, especially episodes of sepsis (2,10). Intravenous  
264 supplementation, overfeeding and a high amount of lipid emulsion are recognized causes of IFALD (2,10).  
265 Similarly, CRBSI occurrence has also previously been reported to occur more frequently in those dependent  
266 on an increased number of days of IVS (8); this may relate to more frequent handling of the central venous  
267 catheter increasing infection risk or the association between macronutrients, vitamins and trace metals  
268 affecting microbial growth in the PN admixture (11,12).

269 Most of the other independent factors found to be associated with patient's outcome and HPN/IF  
270 complications (**Tables 5,6,7**) were in keeping with data from previous studies (2,3,8,10). As expected, non-  
271 transplant surgery was the cause of weaning off HPN in a large percentage of patients (13). Notably, data  
272 on the causes of death on long-term IVS are consistent with previous observations (3-5,13-15), even though  
273 the percentage of HPN-related deaths (4%) was lower than that reported in longer retrospective surveys  
274 (10-14%) (3-5,13-15). This could be due to the short duration of the present follow up, as it is known that  
275 the rate of the HPN-related death increases with the duration of the treatment (4). The 344 episodes of  
276 CRBSI registered in the 1859 patients accounted for a rate of CRBSI of 0.18 per catheter-year, or 0.50 per  
277 1000 catheter-days, a rate that is in the range reported in the literature (2). The 30 new cases of CVC-VT

278 observed at one-year follow up, accounted for an incidence rate of 0.016 per catheter-year, that is also in  
279 the lower range of the literature (0.02-0.09 cases per catheter-year) (2).

280 The weakness of the study is mainly represented by the retrospective analysis of data prospectively  
281 recorded in the previous 12 months, which would imply a risk of some underreporting. However, the  
282 strength of the study is clearly reflected by its international multicenter structure and by the study  
283 population, which is the largest cohort of patients with CIF ever enrolled in a single survey. These  
284 characteristics should avoid the potential bias associated with the analysis of individual center cohorts,  
285 which could be influenced by local practice and expertise, and mitigate the impact of the above possible  
286 weakness on statistical analyses. Furthermore, the agreement between our results and the risk factors,  
287 (other than quantified IVS), reported by previous studies would support the overall reliability of our  
288 findings.

289 In conclusion, the type of the IVS, either FE or PN, and the volume of the PN-admixture, as  
290 categorized by the ESPEN clinical classification of CIF, were found to be independently associated with the  
291 one-year likelihoods of death, of weaning from HPN and of major complications of HPN/IF. These results  
292 support the ESPEN categorization of the IVS as potential marker of the severity of CIF.

293

## References

1. Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, Forbes A, Gabe S, Gillanders L, Holst M, Jeppesen PB, Joly F, Kelly D, Klek S, Irtun Ø, Olde Damink SW, Panisic M, Rasmussen HH, Staun M, Szczepanek K, Van Gossum A, Wanten G, Schneider SM, Shaffer J; Home Artificial Nutrition & Chronic Intestinal Failure and the Acute Intestinal Failure Special Interest Groups of ESPEN. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. *Clin Nutr.* 2015 Apr;34(2):171-80.
2. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, Joly F, Kelly D, Lal S, Staun M, Szczepanek K, Van Gossum A, Wanten G, Schneider SM; Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. *Clin Nutr.* 2016 Apr;35(2):247-307. doi: 10.1016/j.clnu.2016.01.020. Epub 2016 Feb 8. PubMed PMID:26944585.
3. Pironi L, Goulet O, Buchman A, Messing B, Gabe S, Candusso M, Bond G, Gupte G, Pertkiewicz M, Steiger E, Forbes A, Van Gossum A, Pinna AD; Home Artificial Nutrition and Chronic Intestinal Failure Working Group of ESPEN. Outcome on home parenteral nutrition for benign intestinal failure: a review of the literature and benchmarking with the European prospective survey of ESPEN. *Clin Nutr.* 2012 Dec;31(6):831-45. doi: 10.1016/j.clnu.2012.05.004. Epub 2012 Jun 2. Review. PubMed PMID: 22658443.
4. Pironi L, Joly F, Forbes A, Colomb V, Lyszkowska M, Baxter J, Gabe S, Hébuterne X, Gambarara M, Gottrand F, Cuerda C, Thul P, Messing B, Goulet O, Staun M, Van Gossum A; Home Artificial Nutrition & Chronic Intestinal Failure Working Group of the European Society for Clinical Nutrition and Metabolism (ESPEN). Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. *Gut.* 2011 Jan;60(1):17-25. doi: 10.1136/gut.2010.223255. Epub 2010 Nov 10. PubMed PMID: 21068130.
5. Joly F, Baxter J, Staun M, Kelly DG, Hwa YL, Corcos O, De Francesco A, Agostini F, Klek S, Santarpia L, Contaldo F, Jonker C, Wanten G, Chicharro L, Burgos R, Van Gossum A, Cuerda C, Virgili N, Pironi L; ESPEN HAN CIF group. Five-year survival and causes of death in patients on home parenteral

- 321 nutrition for severe chronic and benign intestinal failure. *Clin Nutr.* 2017 Jun 19. pii: S0261-  
322 5614(17)30227-3. doi: 10.1016/j.clnu.2017.06.016. [Epub ahead of print] PubMed PMID: 28701261.
- 323 6. Pironi L, Konrad D, Brandt C, Joly F, Wanten G, Agostini F, Chambrier C, Aimasso U, Zeraschi S, Kelly  
324 D, Szczepanek K, Jukes A, Di Caro S, Theilla M, Kunecki M, Daniels J, Serlie M, Poullenot F, Wu J,  
325 Cooper SC, Rasmussen HH, Compher C, Seguy D, Crivelli A, Pagano MC, Hughes SJ, Guglielmi FW,  
326 Kozjek NR, Schneider SM, Gillanders L, Ellegard L, Thibault R, Matras P, Zmarzly A, Matysiak K, Van  
327 Gossum A, Forbes A, Wyr N, Taus M, Virgili NM, O'Callaghan M, Chapman B, Osland E, Cuerda C,  
328 Sahin P, Jones L, Lee ADW, Bertasi V, Orlandoni P, Izbéki F, Spaggiari C, Díez MB, Doitchinova-  
329 Simeonova M, Garde C, Serralde-Zúñiga AE, Olveira G, Krznaric Z, Czako L, Kekstas G, Sanz-Paris A,  
330 Jáuregui EP, Murillo AZ, Schafer E, Arends J, Suárez-Llanos JP, Shaffer J, Lal S. Clinical classification of  
331 adult patients with chronic intestinal failure due to benign disease: An international multicenter  
332 cross-sectional survey. *Clin Nutr.* 2018 Apr;37(2):728-738. doi: 10.1016/j.clnu.2017.04.013. Epub  
333 2017 Apr 19. PubMed PMID: 28483328.
- 334 7. Agostini F, Sasdelli AS, Guidetti M, Comai G, La Manna G, Pironi L. Outcome of kidney function in  
335 adults on long-term home parenteral nutrition for chronic intestinal failure , *Nutrition* (2018), doi:  
336 <https://doi.org/10.1016/j.nut.2018.10.005>
- 337 8. Dreesen M, Foulon V, Spriet I, Goossens GA, Hiele M, De Pourcq L, Willems L. Epidemiology of  
338 catheter-related infections in adult patients receiving home parenteral nutrition: a systematic  
339 review. *Clin Nutr.* 2013 Feb;32(1):16-26. doi: 10.1016/j.clnu.2012.08.004. Epub 2012 Aug 21. Review.  
340 PubMed PMID: 22959630.
- 341 9. Sasdelli AS, Agostini F, Pazzeschi C, Guidetti M, Lal S, Pironi L. Assessment of Intestinal Failure  
342 Associated Liver Disease according to different diagnostic criteria. *Clin Nutr.* 2018 May 8. pii: S0261-  
343 5614(18)30170-5. doi: 10.1016/j.clnu.2018.04.019. [Epub ahead of print] PubMed PMID: 29778510.
- 344 10. Lal S, Pironi L, Wanten G, Arends J, Bozzetti F, Cuerda C, Joly F, Kelly D, Staun M, Szczepanek K, Van  
345 Gossum A, Schneider SM; Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group  
346 of the European Society for Clinical Nutrition and Metabolism (ESPEN). Clinical approach to the  
347 management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from

- 348 the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. *Clin Nutr.*  
349 2018 Jul 9. pii: S0261-5614(18)31208-1. doi: 10.1016/j.clnu.2018.07.006. [Epub ahead of print]  
350 PubMed PMID: 30017241.
- 351 11. Austin PD, Hand KS, Elia M. Systematic review and meta-analyses of the effect of lipid emulsion on  
352 microbial growth in parenteral nutrition. *J Hosp Infect.* 2016 Dec;94(4):307-319. doi:  
353 10.1016/j.jhin.2016.08.026. Epub 2016 Sep 7. Review. PubMed PMID: 27765342.
- 354 12. Buchman AL, Opilla M, Kwasny M, Diamantidis TG, Okamoto R. Risk factors for the development of  
355 catheter-related bloodstream infections in patients receiving home parenteral nutrition. *JPEN J*  
356 *Parenter Enteral Nutr.* 2014 Aug;38(6):744-9. doi: 10.1177/0148607113491783. Epub 2013 Jun 6.  
357 PubMed PMID: 23744839.
- 358 13. Amiot A, Messing B, Corcos O, Panis Y, Joly F. Determinants of home parenteral nutrition  
359 dependence and survival of 268 patients with non-malignant short bowel syndrome. *Clin Nutr.* 2013  
360 Jun;32(3):368-74. doi: 10.1016/j.clnu.2012.08.007. Epub 2012 Aug 23. PubMed PMID: 22992308.
- 361 14. Dibb M, Soop M, Teubner A, Shaffer J, Abraham A, Carlson G, Lal S. Survival and nutritional  
362 dependence on home parenteral nutrition: Three decades of experience from a single referral  
363 centre. *Clin Nutr...*
- 364 15. Brandt CF, Tribler S, Hvistendahl M, Naimi RM, Brøbech P, Staun M, Jeppesen PB. Home Parenteral  
365 Nutrition in Adult Patients With Chronic Intestinal Failure: Catheter-Related Complications Over 4  
366 Decades at the Main Danish Tertiary Referral Center. *JPEN J Parenter Enteral Nutr.* 2018 Jan;42(1):95-  
367 103. doi: 10.1177/0148607116678766. Epub 2017 Dec 11. PubMed PMID: 29505150.
- 368 16. Pironi L, Corcos O, Forbes A, Holst M, Joly F, Jonkers C, Klek S, Lal S, Blaser AR, Rollins KE, Sasdelli AS,  
369 Shaffer J, Van Gossum A, Wanten G, Zanfi C, Lobo DN; ESPEN Acute and Chronic Intestinal Failure  
370 Special Interest Groups. Intestinal failure in adults: Recommendations from the ESPEN expert groups.  
371 *Clin Nutr.* 2018 Aug 18. pii: S0261-5614(18)31253-6. doi: 10.1016/j.clnu.2018.07.036. [Epub ahead of  
372 print] PubMed PMID: 30172658.



373 **Table 1.** Items of the “Chronic Intestinal Failure (CIF) Action Day” database of the European Society for  
 374 Clinical Nutrition and Metabolism (ESPEN) used for the follow up survey on patient outcome and home  
 375 parenteral nutrition/chronic intestinal failure major complications.  
 376

377 **At baseline**

- 378 • Patient characteristics
  - 379 – Gender
  - 380 – Age (year)
  - 381 – Body height (cm)
  - 382 – Body weight (kg)
  - 383 – Body mass index (BMI) [body weight (kg)/height (m<sup>2</sup>)]
- 384 • CIF characteristics
  - 385 – Pathophysiological mechanism of intestinal failure
    - 386 ▪ Short bowel syndrome with end-jejunostomy (SBS-J)
    - 387 ▪ SBS with jejunocolic anastomosis (SBS-JC)
    - 388 ▪ SBS with jejunoleileal anastomosis and total colon in continuity (SBS-JIC)
    - 389 ▪ Dysmotility
    - 390 ▪ Intestinal fistulas (Fistulas)
    - 391 ▪ Mechanical obstruction (Obstruction)
    - 392 ▪ Extensive small bowel mucosa disease (Mucosal disease)
  - 393 – Underlying disease which causes the intestinal failure
- 394 • HPN program characteristics
  - 395 – HPN duration at patient first inclusion in the database (months)
  - 396 – Intravenous supplementation (IVS)-admixture type
  - 397 – IVS-volume per day of infusion
  - 398 – IVS-total energy per day of infusion
  - 399 – IVS-days of infusion per week
- 400
- 401 • Clinical classification of CIF, based on the IVS type and volume:

Type of the IVS	Volume of the IVS (mL/day)*			
	≤ 1000	1001 - 2000	2001 - 3000	> 3000
<b>Fluids and electrolytes (FE)</b>	FE 1	FE 2	FE 3	FE 4
<b>Parenteral nutrition (PN)</b>	PN 1	PN 2	PN 3	PN 4

- 402 – \* calculated as daily mean of the total volume infused per week = volume per day of infusion x number  
 403 of infusions per week / 7
- 404 – FE, Fluids and Electrolytes alone
- 405 – PN, Parenteral Nutrition Admixture containing also macronutrients

406  
 407  
 408

409 **At follow up**

410 *Patient outcome*

- 411 • Still on HPN:
  - 412 – On standard treatment
  - 413 – On intestinal growth factor
  - 414 – After intestinal transplantation (ITx)
- 415 • Weaned from HPN:
  - 416 – spontaneous adaptation
  - 417 – non-transplant surgery
  - 418 – intestinal growth factor therapy
  - 419 – ITx
- 420 • Deceased:
  - 421 – HPN/CIF complication (CRBSI, CVC-VT, IFALD-cholestasis)
  - 422 – underlying disease complication ( gastrointestinal disease, systemic disease, post-ITx complications
  - 423 or other) (specify)
  - 424 – other causes (specify)
- 425 • Lost to follow up

426 *HPN/IF major complications*

- 427 • Presence of intestinal failure associated liver disease-cholestasis (IFALD-cholestasis) or liver failure:
  - 428 – Cholestasis: total bilirubin >1 mg/dL (>17.1 µmol/L) and direct bilirubin >0.3 mg/dL (>5.2
  - 429 µmol/L)
  - 430 – Impending liver failure: total bilirubin >3 mg/dL (>54.3 µmol/L) with direct bilirubin above the
  - 431 upper normal value, progressive thrombocytopenia and splenomegaly
  - 432 – Overt liver failure: portal hypertension, hepatosplenomegaly, hepatic fibrosis or cirrhosis
- 433 • Presence of central venous catheter venous-associated venous thrombosis (CVC-VT)
- 434 • Occurrence of catheter related bloodstream infection (CRBSI), diagnosed according to local
- 435 protocol, between baseline and follow up

436

---

437

Categories	N. of patients (%)	Mean $\pm$ SD
<b>Gender</b>		
Male	811 (37.0)	
Female	1383 (63.0)	
<b>Age (years)</b>		
		55.1 $\pm$ 16.2
$\leq 29$	187 (8.5)	
30-49	575 (26.2)	
50-69	990 (45.1)	
$\geq 70$	442 (20.1)	
<b>BMI (kg/m<sup>2</sup>)</b>		
		22.3 $\pm$ 4.4
$\leq 15$	57 (2.6)	
15-18.5	324 (14.8)	
18.5-25	1334 (60.8)	
25-30	363 (16.5)	
$\geq 30$	111 (5.1)	
Missing	5 (0.2)	
<b>Duration of IVS (years)</b>		
		4.8 $\pm$ 5.8
$\leq 1$	575 (26.2)	
1-3	575 (26.2)	
3-10	748 (34.1)	
>10	293 (13.4)	
Missing	3 (0.1)	
<b>Mechanism of IF</b>		
SBS-J	788 (35.9)	
SBS-JC	459 (20.9)	
SBS-JIC	140 (6.4)	
Fistulas	149 (6.8)	
Dysmotility	398 (18.1)	
Obstruction	104 (4.7)	
Mucosal disease	156 (7.1)	
<b>Underlying disease</b>		
<i>Crohn's disease</i>	462	
<i>Ulcerative colitis</i>	18	
Total IBD	480 (21.9)	
Mesenteric ischemia	395 (18.0)	
Surgical complications	306 (13.9)	
<i>CIPO primary</i>	222	
<i>CIPO secondary</i>	77	
Total CIPO	299 (13.6)	

<i>Intra-abdominal adhesions</i>	72	
<i>Volvulus</i>	46	
<i>Cured cancer</i>	21	
<i>Abdominal trauma</i>	26	
<i>Intestinal malformation</i>	13	
Total other causes of SBS	178 (8.1)	
<i>Collagenous</i>	40	
<i>Intra-abdominal desmoid</i>	22	
<i>Intestinal polyposis</i>	16	
<i>Autoimmune enteropathy</i>	14	
<i>Neurological disease</i>	11	
<i>Congenital mucosal disease foglio2</i>	14	
<i>Celiac disease</i>	8	
<i>Other diseases</i>	93	
Total miscellaneous	218 (9.9)	
Radiation enteritis	164 (7.5)	
Missing	154 (7.0)	
<b>Clinical classification of CIF (volume/day of infusion)</b>		
FE1 ( ≤1 L)	118 (5.4)	
FE2 (1-2 L)	40 (1.8)	
FE3 (2-3 L)	10 (0.5)	
FE4 ( >3 L)	6 (0.3)	
Total FE	174 (7.9)	1055.8 ± 859.6
PN1 ( ≤1 L)	384 (17.5)	
PN2 (1-2 L)	944 (43.0)	
PN3 (2-3 L)	482 (22.0)	
PN4 ( >3 L)	210 (9.6)	
Total PN	2020 (92.1)	1872.6 ± 972.1

---

439 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome  
440 with jejunostomy; SBS-JC, short bowel syndrome with jejuno-colon anastomosis with partial colon; SBS-JIC,  
441 short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease,  
442 CIPO, chronic intestinal pseudo-obstruction; CIF, chronic intestinal failure; FE, fluid and electrolytes alone;  
443 PN, parenteral nutrition-admixture  
444

445 **Table 3.** Bivariate analysis of factors associated with the one-year outcome of adult patients on home intravenous support for chronic intestinal failure due to  
 446 benign disease.

	<b>Patients</b> n.	<b>Still on HPN</b> n. (%)	<b>Weaned from HPN</b> n. (%)	<b>Deceased</b> n. (%)	<b>P</b>
<b>Gender (n.)</b>					0.144
Male	811	627 (77.3)	125 (15.4)	59 (7.3)	
Female	1383	1113 (80.5)	173 (12.5)	97 (7.0)	
<b>Age (years)</b>					<0.001
≤29	187	147 (78.6)	37 (19.8)	3 (1.6)	
30-49	575	462 (80.3)	93 (16.2)	20 (3.5)	
50-69	990	794 (80.2)	124 (12.5)	72 (7.3)	
≥70	442	337 (76.2)	44 (10.0)	61 (13.8)	
<b>BMI (kg/m<sup>2</sup>)</b>					0.008
≤15	57	46 (80.7)	6 (10.5)	5 (8.8)	
15-18.5	324	241 (74.4)	51 (15.7)	32 (9.9)	
18.5-25	1334	1100 (82.5)	146 (10.9)	88 (6.6)	
25-30	363	274 (75.5)	68 (18.7)	21 (5.8)	
≥30	111	75 (67.6)	27 (24.3)	9 (8.1)	
<b>Duration of IVS (years)</b>					<0.001
≤1	575	345 (60)	182 (31.7)	48 (8.3)	
1-3	575	455 (79.1)	76 (13.2)	44 (7.7)	
3-10	748	670 (89.6)	34 (4.5)	44 (5.9)	
>10	293	268 (91.5)	5 (1.7)	20 (6.8)	
<b>Mechanism of IF (n.)</b>	788				<0.001
SBS-J	459	617 (78.3)	115 (14.6)	56 (7.1)	

SBS-JC	140	405 (88.2)	34 (7.4)	20 (4.4)	
SBS-JIC	149	109 (77.9)	24 (17.1)	7 (5.0)	
Fistulas	398	96 (64.4)	35 (23.5)	18 (12.1)	
Dysmotility	104	325 (81.7)	43 (10.8)	30 (7.5)	
Obstruction	156	73 (70.2)	19 (18.3)	12 (11.5)	
Mucosal disease	788	115 (73.7)	28 (17.9)	13 (8.3)	
<b>Underlying disease (n.)</b>					<0.001
Total IBD	480	383 (79.8)	72 (15.0)	25 (5.2)	
Mesenteric ischemia	395	313 (79.2)	42 (10.6)	40 (10.1)	
Surgical complications	306	215 (70.3)	63 (20.6)	28 (9.2)	
Total CIPO	299	256 (85.6)	31 (10.4)	12 (4.0)	
Other causes of SBS	178	176 (80.7)	21 (9.6)	21 (9.6)	
Miscellaneous	218	136 (76.4)	32 (18.0)	10 (5.6)	
Radiation enteritis	154	135 (82.3)	17 (10.4)	12 (7.3)	
<b>Clinical classification of CIF (n.)</b>					0.190
FE1 ( ≤1 L)	118	106 (89.8)	11 (9.3)	1 (0.8)	
FE2 (1-2 L)	40	31 (77.5)	5 (12.5)	4 (10.0)	
FE3 (2-3 L)	10	8 (80)	2 (20.0)	0	
FE4 ( >3 L)	6	5 (83.3)	1 (16.7)	0	
PN1 ( ≤1 L)	384	296 (77.1)	65 (16.9)	23 (6.0)	
PN2 (1-2 L)	944	745 (78.9)	126 (13.3)	73 (7.7)	
PN3 (2-3 L)	482	378 (78.4)	65 (13.5)	39 (8.1)	
PN4 ( >3 L)	210	171 (81.4)	23 (11.0)	16 (7.6)	
<b>Type of IVS (n.)</b>					0.032
Total FE	174	150 (86.2)	19 (10.9)	5 (2.9)	
Total PN	2020	1590 (78.7)	279 (13.8)	151 (7.5)	

---

447 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with  
448 jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejunio-ileo anastomosis with intact colon; IBD, inflammatory bowel disease,  
449 CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral  
450 nutrition-admixture

451 **Table 4.** Bivariate analysis of factors associated with the major home parenteral nutrition/ intestinal failure complications during a one-year follow up in adult  
 452 patients on home intravenous support for chronic intestinal failure due to non malignant disease, categorized according to clinical, home parenteral nutrition  
 453 and referral center characteristics (IFALD, intestinal failure associated liver disease: cholestasis of impending/overt liver failure; CVC-VT. Central venous  
 454 catheter-associated deep vein thrombosis; CRBSI, catheter related bloodstream infections)

	Presence of IFALD*			Presence of CVC-VT			Occurrence of CRBSI		
	Patients n.	n. (%)	P	Patients n.	n. (%)	P	Patients n.	n. (%)	P
<b>Gender (n.)</b>			0.029			0.689			0.886
Male	642	46 (6.7)		667	21 (3.1)		585	102 (14.8)	
Female	1120	51 (4.4)		1139	32 (2.7)		1000	171 (14.6)	
<b>Age (years)</b>			0.253			0.855			0.001
≤29	148	13 (8.1)		158	3 (1.9)		122	39 (24.2)	
30-49	456	28 (5.8)		469	15 (3.1)		404	79 (16.4)	
50-69	801	37 (4.4)		813	25 (2.5)		735	103 (12.3)	
≥70	357	19 (5.1)		366	10 (2.7)		324	52 (13.8)	
<b>BMI (kg/m<sup>2</sup>)</b>			0.533			0.281			0.019
≤15	45	3 (6.3)		158	2 (4.2)		41	7 (14.6)	
15-18.5	238	16 (6.3)		469	12 (4.7)		217	37 (14.6)	
18.5-25	1075	63 (5.5)		813	27 (2.4)		986	151 (13.3)	
25-30	303	12 (3.8)		366	8 (2.5)		262	53 (16.8)	
≥30	96	3 (3.0)		158	4 (4.0)		74	25 (25.3)	
<b>Duration of IVS (years)</b>			0.980			0.010			0.549
≤1	442	25 (5.4)		461	6 (1.3)		398	69 (14.8)	
1-3	449	23 (4.9)		463	9 (1.9)		396	76 (16.1)	
3-10	611	34 (5.3)		619	26 (4.0)		550	95 (14.7)	
>10	257	15 (5.5)		260	12 (4.4)		238	33 (12.2)	



<b>Mechanism of IF (n.)</b>			0.540			0.038		0.674
SBS-J	633	51 (7.5)		670	14 (2.0)		584	100 (14.6)
SBS-JC	357	15 (4.0)		352	20 (5.4)		326	45 (12.1)
SBS-JIC	108	5 (4.4)		110	3 (2.7)		92	21 (18.6)
Fistulas	120	5 (4.0)		124	1 (0.8)		104	21 (16.8)
Dysmotility	335	10 (2.9)		334	11 (3.2)		291	54 (15.7)
Obstruction	85	5 (5.6)		89	1 (1.1)		77	13 (14.4)
Mucosal disease	124	6 (4.6)		670	3 (2.3)		111	19 (14.6)
<b>Underlying disease (n.)</b>			0.156			0.060		0.023
Total IBD	406	19 (4.5)		417	8 (1.9)		375	50 (11.8)
Mesenteric ischemia	294	20 (6.4)		300	14 (4.5)		272	42 (13.4)
Surgical complications	238	19 (7.4)		254	3 (1.2)		215	42 (16.3)
Total CIPO	255	9 (3.4)		257	7 (2.7)		214	50 (18.9)
Other causes of SBS	129	8 (5.8)		130	7 (5.1)		110	26 (19.1)
Miscellaneous	164	13 (7.3)		169	8 (4.5)		143	34 (19.2)
Radiation enteritis	129	3 (2.3)		130	2 (1.5)		119	13 (9.8)
<b>Clinical classification of IF (n.)</b>			<0.001			0.005		0.005
FE1 ( ≤1 L)	105	1 (0.9)		105	1 (0.9)		99	7 (6.6)
FE2 (1-2 L)	36	1 (2.7)		37	0		33	4 (10.8)
FE3 (2-3 L)	9	0		7	2 (22.2)		7	2 (22.2)
FE4 ( >3 L)	5	1 (16.7)		6	0		6	0
PN1 ( ≤1 L)	302	6 (1.9)		294	14 (4.5)		275	33 (10.7)
PN2 (1-2 L)	768	30 (3.8)		773	25 (3.1)		678	120 (15.0)
PN3 (2-3 L)	374	35 (8.6)		401	8 (2.0)		342	66 (16.2)
PN4 ( >3 L)	163	23 (12.4)		183	3 (1.6)		145	41 (22.0)
<b>Type of IVS (n.)</b>			0.050			0.452		0.016
Total FE	155	3 (1.9)		155	2 (1.9)		145	13 (8.2)
Total PN	1607	94 (5.5)		1701	50 (2.9)		1440	260 (15.3)

---

455 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with  
456 jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejuno-ileo anastomosis with intact colon; IBD, inflammatory bowel disease,  
457 CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral  
458 nutrition-admixture  
459  
460

461 **Table 5.** Multivariate analysis of factors independently associated with the likelihoods of weaning from IVS and of death in adult patients with CIF

Independent factors	Patients weaned form HPN				Patients deceased			
	Association with IVS type (n. 278)		Association with PN volume (n. 259)		Association with IVS type (n. 147)		Association with PN volume (n. 142)	
	P	OR	P	OR	P	OR	P	OR
<b>IVS type and volume</b>								
Total FE1	Comparator				Comparator			
PN1 (≤1 L)	<b>0.002</b>	<b>2.726</b>	Comparator		0.066	Comparator		
PN2 (1-2 L)	0.539		<b>&lt;0.001</b>	<b>0.428</b>	<b>0.025</b>	<b>3.001</b>	0.665	
PN3 (2-3 L)	0.335		<b>0.002</b>	<b>0.491</b>	<b>0.016</b>	<b>3.343</b>	0.456	
PN4 (>3 L)	0.907		<b>0.002</b>	<b>0.372</b>	<b>0.019</b>	<b>3.611</b>	0.420	
<b>Gender</b>								
Male	Comparator							
Female	0.173		0.081		0.684		0.848	
<b>Age (years)</b>								
≤29	Comparator							
30-49	0.086		0.057		0.244		0.233	
50-69	<b>0.003</b>	<b>0.462</b>	<b>0.006</b>	<b>0.484</b>	<b>0.015</b>	<b>4.531</b>	<b>0.017</b>	<b>4.433</b>
≥70	<b>0.002</b>	<b>0.393</b>	<b>0.001</b>	<b>0.353</b>	<b>&lt;0.001</b>	<b>9.602</b>	<b>&lt;0.001</b>	<b>9.412</b>
<b>BMI (kg/m<sup>2</sup>)</b>								
18.5-25.0	Comparator							
≤15.0	0.281		0.338		0.063		0.074	
15.0-18.5	0.057		<b>0.034</b>	<b>1.573</b>	<b>0.006</b>	<b>1.960</b>	<b>0.011</b>	<b>1.891</b>
25.1-30.0	<b>0.002</b>	<b>1.835</b>	<b>0.002</b>	<b>1.850</b>	0.440		0.416	
≥30.0	<b>0.017</b>	<b>2.010</b>	<b>0.001</b>	<b>2.826</b>	0.174		0.223	

**Duration of IVS (years)**

≤1	Comparator						
1-3	<0.001	0.266	<0.001	0.268	0.545	0.411	
3-10	<0.001	0.086	<0.001	0.080	0.081	0.041	0.605
>10	<0.001	0.028	<0.001	0.030	0.607	0.609	

**Mechanism of IF**

SBS-J	Comparator						
SBS-JC	0.095		0.082	0.008	0.452	0.007	0.438
SBS-JIC	0.214		0.272	0.216		0.263	
Fistulas	0.147		0.154	0.022	2.162	0.014	2.347
Dysmotility	0.696		0.411	0.021	2.344	0.019	2.401
Obstruction	0.391		0.300	0.043	2.333	0.045	2.335
Mucosal disease	0.396		0.282	0.246		0.194	

**Underlying disease**

Total IBD	Comparator						
Total CIPO	0.153		0.099	0.033	0.354	0.052	
Other causes of SBS	0.160		0.168	0.753		0.949	
Miscellaneous	0.008	0.436	0.011	0.442	0.866	0.704	
Mesenteric ischemia	0.298		0.483	0.025	1.946	0.013	2.164
Radiation enteritis	0.514		0.718	0.406		0.595	
Surgical complications	0.408		0.587	0.521		0.414	

---

462 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with  
463 jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejunio-ileo anastomosis with intact colon; IBD, inflammatory bowel disease,  
464 CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral  
465 nutrition-admixture  
466

467 **Table 6.** Multivariate analysis of factors independently associated with the likelihoods of weaning from IVS without an intestinal surgical procedure in adult  
 468 patients with CIF

Independent factors	Patients weaned form HPN			
	Association with IVS type (n. 174)		Association with PN volume (n. 162)	
	P	OR	P	OR
<b>IVS type and volume</b>				
Total FE1	Comparator		Comparator	
PN1 (≤1 L)	<b>0.049</b>	<b>2.094</b>		
PN2 (1-2 L)	0.862		<b>&lt;0.001</b>	<b>0.433</b>
PN3 (2-3 L)	0.762		<b>0.002</b>	<b>0.419</b>
PN4 (>3 L)	0.459		<b>0.011</b>	<b>0.327</b>
<b>Gender</b>				
Male	Comparator			
Female	0.760		0.554	
<b>Age (years)</b>				
≤29	Comparator			
30-49	<b>0.031</b>	<b>0.543</b>	<b>0.024</b>	<b>0.517</b>
50-69	<b>0.002</b>	<b>0.408</b>	<b>0.003</b>	<b>0.425</b>
≥70	<b>0.001</b>	<b>0.296</b>	<b>&lt;0.001</b>	<b>0.251</b>
<b>BMI (kg/m<sup>2</sup>)</b>				
18.5-25.0	Comparator			
≤15.0	0.367		0.420	
15.0-18.5	0.096		0.076	
25.1-30.0	0.097		0.053	
≥30.0	0.173		0.056	

<b>Duration of IVS (years)</b>				
≤1	Comparator			
1-3	<b>&lt;0.001</b>	<b>0.332</b>	<b>&lt;0.001</b>	<b>0.320</b>
3-10	<b>&lt;0.001</b>	<b>0.139</b>	<b>&lt;0.001</b>	<b>0.123</b>
>10	<b>&lt;0.001</b>	<b>0.047</b>	<b>&lt;0.001</b>	<b>0.049</b>

<b>Mechanism of IF</b>				
SBS-J	Comparator			
SBS-JC	0.318		0.236	
SBS-JIC	<b>&lt;0.001</b>	<b>3.459</b>	<b>&lt;0.001</b>	<b>3.684</b>
Fistulas	<b>&lt;0.001</b>	<b>3.387</b>	<b>&lt;0.001</b>	<b>3.710</b>
Dysmotility	<b>0.011</b>	<b>2.707</b>	<b>0.002</b>	<b>3.536</b>
Obstruction	<b>0.049</b>	<b>2.387</b>	<b>0.026</b>	<b>2.762</b>
Mucosal disease	<b>0.003</b>	<b>2.699</b>	<b>0.001</b>	<b>3.165</b>

<b>Underlying disease</b>				
Total IBD	Comparator			
Total CIPO	0.087		<b>0.042</b>	<b>0.403</b>
Other causes of SBS	0.859		0.871	
Miscellaneous	<b>0.013</b>	<b>0.427</b>	<b>0.013</b>	<b>0.417</b>
Mesenteric ischemia	0.237		0.338	
Radiation enteritis	0.119		0.193	
Surgical complications	0.540		0.346	

---

469 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with  
470 jejuno-colon anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejunio-ileo anastomosis with intact colon; IBD, inflammatory bowel disease,  
471 CIPO, chronic intestinal pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral  
472 nutrition-admixture  
473

474 **Table 7.** Multivariate analysis of factors associated with the likelihoods of major HPN/IF complications in adult patients with CIF

Independent factors	Presence of IFALD-cholestasis/impending or overt liver failure				Presence of CVC-vein thrombosis				Occurrence of CRBSI			
	Association with IVS type (n.91)		Association with PN volume (n.88)		Association with IVS type (n.49)		Association with PN volume (n.47)		Association with IVS type (n.257)		Association with PN volume (n.244)	
	P	OR	P	OR	P	OR	P	OR	P	OR	P	OR
<b>IVs type and volume</b>												
Total FE1	Comparator				Comparator				Comparator			
PN1 (≤1 L)	0.831		Comparator		0.246		Comparator		0.362		Comparator	
PN2 (1-2 L)	0.227		0.175		0.380		0.530		<b>0.024</b>		<b>2.079</b> 0.071	
PN3 (2-3 L)	<b>0.017</b>	<b>4.437</b>	<b>0.004</b>	<b>3.881</b>	0.746		0.183		<b>0.015</b>	<b>2.264</b>	<b>0.043</b>	<b>1.654</b>
PN4 (>3 L)	<b>0.007</b>	<b>5.692</b>	<b>0.001</b>	<b>5.008</b>	0.827		0.329		<b>&lt;0.001</b>	<b>3.543</b>	<b>0.001</b>	<b>2.614</b>
<b>Gender</b>												
Male	Comparator											
Female	0.121		0.205		0.482		0.326		0.658		0.566	
<b>Age (years)</b>												
≤29	Comparator											
30-49	0.486		0.499		0.329		0.392		<b>0.046</b>		<b>0.620</b> <b>0.047</b> <b>0.616</b>	
50-69	0.358		0.306		0.228		0.217		<b>0.005</b>		<b>0.507</b> <b>0.007</b> <b>0.516</b>	
≥70	0.637		0.615		0.419		0.482		0.058		0.093	
<b>BMI (kg/m<sup>2</sup>)</b>												
18.5-25	Comparator											
≤15	0.916		0.947		0.188		0.183		0.834		0.806	
15-18.5	0.116		0.196		<b>0.011</b>		<b>2.643</b> <b>0.009</b> <b>2.746</b>		0.569		0.785	
25-30	0.152		0.220		0.757		0.713		0.054		0.117	
≥30	0.404		0.310		0.123		0.064		<b>0.001</b>		<b>2.583</b> <b>0.012</b> <b>2.199</b>	
<b>Duration of HPN (years)</b>												

≤1	Comparator							
1-3	0.94	0.867	0.405	1.573	0.227	2.006	0.426	0.317
3-10	0.839	0.667	0.054	2.540	<b>0.035</b>	<b>3.025</b>	0.669	0.798
>10	0.949	0.931	<b>0.036</b>	<b>3.105</b>	<b>0.019</b>	<b>3.873</b>	0.516	0.405

#### Mechanism of IF

SBS-J	Comparator							
SBS-JC	0.190	0.23	0.215		0.168		0.722	0.994
SBS-JIC	0.434	0.513	0.874		0.969		0.191	0.180
Fistulas	0.304	0.421	0.578		0.678		0.542	0.603
Dysmotility	<b>0.026</b>	<b>0.314</b>	<b>0.036</b>	<b>0.330</b>	0.654	0.590	0.290	0.428
Obstruction	0.917	0.878	0.470		0.563		0.470	0.558
Mucosal disease	0.526	0.556	0.948		0.895		0.769	0.972

#### Underlying disease

Total IBD	Comparator							
Total CIPO	0.510	0.598	0.889		0.848		<b>0.041</b>	<b>1.982</b> 0.074
Other causes of SBS	0.581	0.686	0.077		0.156		0.080	0.132
Miscellaneous	0.079	0.105	0.123		0.109		<b>0.034</b>	<b>1.775</b> 0.055
Mesenteric ischemia	0.273	0.323	0.111		0.099		0.796	0.976
Radiation enteritis	0.454	0.421	0.799		0.928		0.857	0.722
Surgical complications	<b>0.027</b>	<b>2.219</b>	0.112		0.557		0.658	0.470 0.455

475 BMI, body mass index; HPN, home parenteral nutrition; IF, intestinal failure; SBS-J, short bowel syndrome with jejunostomy; SBS-JC, short bowel syndrome with jejunocolon  
476 anastomosis with partial colon; SBS-JIC, short bowel syndrome with jejunocolon anastomosis with intact colon; IBD, inflammatory bowel disease, CIPO, chronic intestinal  
477 pseudo-obstruction; CIF chronic intestinal failure; IVS, intravenous supplementation; FE, fluid and electrolytes alone; PN, parenteral nutrition-admixture  
478

479